Tarsus Pharmaceuticals’ (TARS) Buy Rating Reaffirmed at Guggenheim
Guggenheim restated their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. Several other research analysts have also commented on the stock. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” […]
Guggenheim restated their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. Several other research analysts have also commented on the stock. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” […]
